It is unlikely to be a treatment option for the majority. It also seems to be a relatively short lived effect. In the first trial the outcomes were not very significantly different 12 months after end of treatment.
“The overall proportion of patients who required second-line therapy, either during the index hospitalization or during the 12-month follow-up, was similar between HBOT and sham-treated patients (HBOT 60% vs. sham 88%, p = 0.31).”
The results of the second trial were more positive but follow up was only to 3 months.
Reading around it it seems HBOT may work in part by its positive effect on aryl hydrocarbon receptors.
https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6044055/Qing Dai/indigo naturalis also has this effect and is widely available and affordable. Orally it can have side effects but compares very favourably to conventional therapy in this respect and in effectiveness. .